Guggenheim Capital
MTNB icon

Guggenheim Capital’s Matinas BioPharma MTNB Stock Holding History

Guggenheim Capital’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-28
Closed -$16K – 2521
2018
Q1 		$16K Hold
28
– – ﹤0.01% 2754
2017
Q4 		$23K Buy
+28
New +$27K ﹤0.01% 2666

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Raymond James Financial Services Advisors
Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Element Capital Management
Element Capital Management New York $3.2B AUM 29.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PP
Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return
BlueCrest Capital Management
BlueCrest Capital Management St Helier, Jersey $3.04B AUM 26.78% 1-Year Est. Return

Guggenheim Capital's MTNB Position: Q2 2018 in Review

Guggenheim Capital sold out of Matinas BioPharma (MTNB) in Q2 2018, closing a stake of 28 shares — an estimated $16K sold.

Guggenheim Capital first reported a position in MTNB in Q4 2017 and held it in 2 quarters. The position peaked at $23K in Q4 2017. 38 funds tracked by Wall St. Rank hold MTNB as of Q2 2018.

  • Guggenheim Capital reported no remaining Matinas BioPharma position as of Q2 2018 after selling out during the quarter.
  • Guggenheim Capital sold 28 Matinas BioPharma shares in Q2 2018, an estimated $16K.
  • Guggenheim Capital first reported a position in Matinas BioPharma in Q4 2017 and held it in 2 quarters.
  • Guggenheim Capital's Matinas BioPharma position peaked at $23K in Q4 2017.
  • 38 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2018.

Based on Guggenheim Capital's 13F filing for Q2 2018, filed 14 Aug 2018.